1. Home
  2. BOLT vs KUKE Comparison

BOLT vs KUKE Comparison

Compare BOLT & KUKE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BOLT
  • KUKE
  • Stock Information
  • Founded
  • BOLT 2015
  • KUKE 2002
  • Country
  • BOLT United States
  • KUKE China
  • Employees
  • BOLT N/A
  • KUKE N/A
  • Industry
  • BOLT Biotechnology: Pharmaceutical Preparations
  • KUKE Other Consumer Services
  • Sector
  • BOLT Health Care
  • KUKE Real Estate
  • Exchange
  • BOLT Nasdaq
  • KUKE Nasdaq
  • Market Cap
  • BOLT 22.6M
  • KUKE 18.9M
  • IPO Year
  • BOLT 2021
  • KUKE 2021
  • Fundamental
  • Price
  • BOLT $0.49
  • KUKE $0.31
  • Analyst Decision
  • BOLT Hold
  • KUKE
  • Analyst Count
  • BOLT 5
  • KUKE 0
  • Target Price
  • BOLT $1.25
  • KUKE N/A
  • AVG Volume (30 Days)
  • BOLT 114.3K
  • KUKE 126.0K
  • Earning Date
  • BOLT 03-20-2025
  • KUKE 04-15-2025
  • Dividend Yield
  • BOLT N/A
  • KUKE N/A
  • EPS Growth
  • BOLT N/A
  • KUKE N/A
  • EPS
  • BOLT N/A
  • KUKE N/A
  • Revenue
  • BOLT $9,779,000.00
  • KUKE $14,784,158.00
  • Revenue This Year
  • BOLT $9.87
  • KUKE N/A
  • Revenue Next Year
  • BOLT N/A
  • KUKE N/A
  • P/E Ratio
  • BOLT N/A
  • KUKE N/A
  • Revenue Growth
  • BOLT 35.86
  • KUKE 10.48
  • 52 Week Low
  • BOLT $0.46
  • KUKE $0.23
  • 52 Week High
  • BOLT $1.56
  • KUKE $4.07
  • Technical
  • Relative Strength Index (RSI)
  • BOLT 45.52
  • KUKE 34.52
  • Support Level
  • BOLT $0.48
  • KUKE $0.36
  • Resistance Level
  • BOLT $0.52
  • KUKE $0.50
  • Average True Range (ATR)
  • BOLT 0.03
  • KUKE 0.06
  • MACD
  • BOLT 0.00
  • KUKE -0.01
  • Stochastic Oscillator
  • BOLT 40.32
  • KUKE 4.92

About BOLT Bolt Biotherapeutics Inc.

Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.

About KUKE Kuke Music Holding Limited

Kuke Music Holding Ltd provides classical music licensing, subscription, and education services in China. The company licenses its music content to online music entertainment platforms, such as Tencent Music Entertainment Group, digital music service providers, such as NetEase Cloud Music, as well as film and TV production companies, airlines, and smart hardware companies. Users can access the platform through the website, mobile app, and smart music devices.

Share on Social Networks: